<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00998361</url>
  </required_header>
  <id_info>
    <org_study_id>CE_clin.42_2009_S_sper</org_study_id>
    <nct_id>NCT00998361</nct_id>
  </id_info>
  <brief_title>Hematopoietic Stem Cell Transplantation From Human Leukocyte Antigen (HLA) Compatible Donor in Ewing Sarcomas and Soft Tissues Sarcomas</brief_title>
  <official_title>Hematopoietic Stem Cell Transplantation From HLA Compatible Donor in Ewing Sarcomas and Soft Tissues Sarcomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Orsola Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>S. Anna Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>St. Orsola Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a perspective multicentric study for the treatment of patients aged equal or less
      than 60 years and submitted to an allogeneic hematopoietic stem cell transplantation from an
      HLA compatible related or unrelated donor because affected by resistent or refractory or
      relapsed after autologous stem cell transplantation Ewing Sarcoma or Soft tissues sarcoma who
      did not benefit from conventional therapy.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>June 2009</start_date>
  <completion_date type="Anticipated">June 2011</completion_date>
  <primary_completion_date type="Anticipated">June 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival (PFS) a 12 months from the enrollment higher than 30% for the patients submitted to allogeneic stem cell transplantation in front of the patients who received conventional chemotherapy.</measure>
    <time_frame>12 months from the enrollement</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Transplant related mortality</measure>
    <time_frame>12 months after the enrollement of the first patients</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">140</enrollment>
  <condition>Ewing</condition>
  <condition>Soft Tissue Sarcoma</condition>
  <arm_group>
    <arm_group_label>Stem Cell Transplant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All the patient who are affected by refractory or resistant or relapsed Soft tissue sarcoma o Ewing sarcoma who find an HLA compatible allogeneic donor and are submitted to Stem cell transplantation</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Allogeneic hemopoietic stem cell transplant</intervention_name>
    <description>administration of 15 mg/kg of thiotepa + 140 mg/sqm of melphalan followed by infusion of allogeneic hemopoietic stem cell</description>
    <arm_group_label>Stem Cell Transplant</arm_group_label>
    <other_name>CE_clin.42_2009_S_sper</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 0-60 years.

          -  Performance status according to Karnofsky score &gt; 70%

          -  Normal liver function

          -  Normal renal function

          -  Normal cardiac function

          -  Informed consent

          -  Availability of an HLA compatible Donor

        Exclusion Criteria:

          -  Absence of at least one of the inclusion criteria
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Month</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arcangelo Prete, MD, PhD, PI</last_name>
    <role>Principal Investigator</role>
    <affiliation>S. Orsola-Malpighi Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pediatric Oncology and Hematology Department, S. Orsola-Malpighi Hospital</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>October 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 18, 2009</study_first_submitted>
  <study_first_submitted_qc>October 19, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2009</study_first_posted>
  <last_update_submitted>October 19, 2009</last_update_submitted>
  <last_update_submitted_qc>October 19, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 20, 2009</last_update_posted>
  <responsible_party>
    <name_title>Dr Augusto Cavina</name_title>
    <organization>S. Orsola-Malpighi Hospital</organization>
  </responsible_party>
  <keyword>Sarcoma</keyword>
  <keyword>allogeneic</keyword>
  <keyword>Hemopoietic stem cell transplant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Sarcoma, Ewing</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

